Record Information |
---|
Version | 5.0 |
---|
Status | Detected and Quantified |
---|
Creation Date | 2007-04-12 18:30:36 UTC |
---|
Update Date | 2020-02-26 21:26:09 UTC |
---|
HMDB ID | HMDB0005949 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Lithium |
---|
Description | Lithium (Li) is an alkali metal. First described as a mood stabilizer in 1949, it remains an efficacious treatment for bipolar disorders. Recent emerging evidence of its neuroprotective and neurogenic effects alludes to lithium's potential therapeutic use in stroke and neurodegenerative diseases. One intriguing clinical application is in the treatment of Alzheimer's disease. Ongoing clinical trials are evaluating lithium's abilities to lower tau and beta-amyloid levels in cerebrospinal fluid in Alzheimer's patients. Lithium reduces brain inositol levels by inhibiting the enzyme inositol monophosphatase. This suggests that inositol monophosphatase inhibition is a key mechanism of Li's therapeutic action and that design of new inositol monophosphatase inhibitors may be a practical strategy to create new compounds with Li-like therapeutic effects. Lithium reduces the severity of some behavioral complications of Alzheimer's disease (AD). And there are growing indications that Li may be of benefit to the underlying pathology of AD, as well as an array of other common CNS disorders, including stroke, Parkinson's disease, and Huntington's disease. Physiologically, it exists as an ion in the body. Despite these demonstrated and prospective therapeutic benefits, Li's mechanism of action remains elusive, and opinions differ regarding the most relevant molecular targets. Lithium inhibits several enzymes; significant among these are inositol monophosphatase (IMPase), glycogen synthase kinase-3 (GSK-3), and the proteasome. Lithium has a narrow therapeutic range, and several well characterised adverse effects limit the potential usefulness of higher doses. Acute ingestion in Li-naive patients is generally associated with only short-lived exposure to high concentrations, due to extensive distribution of Li throughout the total body water compartment. Conversely, chronic toxicity and acute-on-therapeutic ingestion are associated with prolonged exposure to higher tissue concentrations and, therefore, greater toxicity. Lithium toxicity may be life threatening, or result in persistent cognitive and neurological impairment. Therefore, enhanced Li clearance has been explored as a means of minimizing exposure to high tissue concentrations. Although haemodialysis is highly effective in removing circulating Li, serum concentrations often rebound so repeated or prolonged treatment may be required. Continuous arteriovenous haemodiafiltration and continuous venovenous haemodiafiltration increase Li clearance, albeit to a lesser extent than haemodialysis, and are more widely accessible. Lithium reduces brain inositol levels by inhibiting IMPase, suggesting that IMPase's inhibition is a key mechanism of Li's therapeutic action and that design of new IMPase inhibitors may be a practical strategy to create new compounds with Li-like therapeutic effects. (PMID: 17688381 , 17316163 , 8110911 , 17288494 ). |
---|
Structure | |
---|
Synonyms | Value | Source |
---|
Li(+) | ChEBI | Lithium cation | ChEBI | LITHIUM ion | ChEBI | Lithium, ion | ChEBI | Lithium, ion (li1+) | ChEBI | Li | HMDB | Li(+) cation | HMDB | Li(+) ion | HMDB | Lithium atom | HMDB | Lithium element | HMDB |
|
---|
Chemical Formula | Li |
---|
Average Molecular Weight | 6.941 |
---|
Monoisotopic Molecular Weight | 7.016004049 |
---|
IUPAC Name | lithium(1+) ion |
---|
Traditional Name | lithium(1+) ion |
---|
CAS Registry Number | 7439-93-2 |
---|
SMILES | [Li+] |
---|
InChI Identifier | InChI=1S/Li/q+1 |
---|
InChI Key | HBBGRARXTFLTSG-UHFFFAOYSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of inorganic compounds known as homogeneous alkali metal compounds. These are inorganic compounds containing only metal atoms,with the largest atom being a alkali metal atom. |
---|
Kingdom | Inorganic compounds |
---|
Super Class | Homogeneous metal compounds |
---|
Class | Homogeneous alkali metal compounds |
---|
Sub Class | Not Available |
---|
Direct Parent | Homogeneous alkali metal compounds |
---|
Alternative Parents | Not Available |
---|
Substituents | |
---|
Molecular Framework | Not Available |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | Biological locationSourceExogenousFoodAnimal originFruitVegetablePulseCereal and cereal productGourdHerb and spiceMilk and milk productUnfermented milk- Milk (Cow) (FooDB: FOOD00618)
- Cow milk, pasteurized, vitamin A + D added, 0% fat (FooDB: FOOD00889)
- Cow milk, pasteurized, vitamin A + D added, 1% fat (FooDB: FOOD00890)
- Cow milk, pasteurized, vitamin A + D added, 2% fat (FooDB: FOOD00891)
- Cow milk, pasteurized, vitamin D added, 3.25% fat (FooDB: FOOD00892)
|
---|
Process | |
---|
Role | |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | 190 °C | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | Not Available | Not Available | LogP | Not Available | Not Available |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredictor | Adduct Type | CCS Value (Å2) | Reference |
---|
DeepCCS | [M+H]+ | 109.705 | 30932474 | DeepCCS | [M-H]- | 107.982 | 30932474 | DeepCCS | [M-2H]- | 143.216 | 30932474 | DeepCCS | [M+Na]+ | 116.531 | 30932474 |
Predicted Kovats Retention IndicesUnderivatized |
---|
Spectra |
---|
| MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lithium 10V, Positive-QTOF | splash10-0a4i-9000000000-d37172edddcf6ff27879 | 2015-09-15 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lithium 20V, Positive-QTOF | splash10-0a4i-9000000000-d37172edddcf6ff27879 | 2015-09-15 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lithium 40V, Positive-QTOF | splash10-0a4i-9000000000-d37172edddcf6ff27879 | 2015-09-15 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lithium 10V, Negative-QTOF | splash10-0a4i-9000000000-00619c7d65eb4b7f8f3d | 2015-09-15 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lithium 20V, Negative-QTOF | splash10-0a4i-9000000000-00619c7d65eb4b7f8f3d | 2015-09-15 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lithium 40V, Negative-QTOF | splash10-0a4i-9000000000-00619c7d65eb4b7f8f3d | 2015-09-15 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lithium 10V, Positive-QTOF | splash10-0a4i-9000000000-29e69b4fc922829a038d | 2021-09-24 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lithium 20V, Positive-QTOF | splash10-0a4i-9000000000-29e69b4fc922829a038d | 2021-09-24 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Lithium 40V, Positive-QTOF | splash10-0a4i-9000000000-29e69b4fc922829a038d | 2021-09-24 | Wishart Lab | View Spectrum |
|
---|
Biological Properties |
---|
Cellular Locations | Not Available |
---|
Biospecimen Locations | - Blood
- Cerebrospinal Fluid (CSF)
- Saliva
- Urine
|
---|
Tissue Locations | Not Available |
---|
Pathways | |
---|
Normal Concentrations |
---|
| |
Blood | Detected and Quantified | 0.040-0.240 uM | Adult (>18 years old) | Both | Normal | | details | Blood | Detected and Quantified | 0.14 +/- 0.10 uM | Adult (>18 years old) | Both | Normal | | details | Cerebrospinal Fluid (CSF) | Detected and Quantified | 10.383 +/- 4.679 uM | Adult (>18 years old) | Not Specified | Normal | | details | Saliva | Detected and Quantified | 92.206-1844.115 uM | Adult (>18 years old) | Not Specified | Normal | | details | Saliva | Detected and Quantified | 2.537 +/- 0.793 uM | Adult (>18 years old) | Both | Normal | | details | Urine | Detected and Quantified | 0.5 (0.2-0.9) umol/mmol creatinine | Adult (>18 years old) | Both | Normal | | details | Urine | Detected and Quantified | 0.504 (0.058-3.414) umol/mmol creatinine | Adult (>18 years old) | Not Specified | Normal | | details |
|
---|
Abnormal Concentrations |
---|
| |
Blood | Detected and Quantified | 0.12 +/- 0.05 uM | Adult (>18 years old) | Both | Multiple sclerosis | | details | Blood | Detected and Quantified | 0.11 +/- 0.085 uM | Adult (>18 years old) | Both | Parkinson's disease | | details | Blood | Detected and Quantified | 0.16 +/- 0.074 uM | Elderly (>65 years old) | Both | Alzheimer's disease | | details | Saliva | Detected and Quantified | 750 +/- 260 uM | Adult (>18 years old) | Male | Mental disorder | | details | Saliva | Detected and Quantified | 760 +/- 230 uM | Adult (>18 years old) | Female | Mental disorder | | details |
|
---|
Associated Disorders and Diseases |
---|
Disease References | Alzheimer's disease |
---|
- Bocca B, Forte G, Petrucci F, Pino A, Marchione F, Bomboi G, Senofonte O, Giubilei F, Alimonti A: Monitoring of chemical elements and oxidative damage in patients affected by Alzheimer's disease. Ann Ist Super Sanita. 2005;41(2):197-203. [PubMed:16244393 ]
| Multiple sclerosis |
---|
- Forte G, Visconti A, Santucci S, Ghazaryan A, Figa-Talamanca L, Cannoni S, Bocca B, Pino A, Violante N, Alimonti A, Salvetti M, Ristori G: Quantification of chemical elements in blood of patients affected by multiple sclerosis. Ann Ist Super Sanita. 2005;41(2):213-6. [PubMed:16244395 ]
| Parkinson's disease |
---|
- Forte G, Alimonti A, Pino A, Stanzione P, Brescianini S, Brusa L, Sancesario G, Violante N, Bocca B: Metals and oxidative stress in patients with Parkinson's disease. Ann Ist Super Sanita. 2005;41(2):189-95. [PubMed:16244392 ]
|
|
---|
Associated OMIM IDs | |
---|
External Links |
---|
DrugBank ID | DB01356 |
---|
Phenol Explorer Compound ID | Not Available |
---|
FooDB ID | FDB004181 |
---|
KNApSAcK ID | Not Available |
---|
Chemspider ID | 26502 |
---|
KEGG Compound ID | C15473 |
---|
BioCyc ID | LI%2b |
---|
BiGG ID | Not Available |
---|
Wikipedia Link | Lithium |
---|
METLIN ID | Not Available |
---|
PubChem Compound | 28486 |
---|
PDB ID | LI |
---|
ChEBI ID | 49713 |
---|
Food Biomarker Ontology | Not Available |
---|
VMH ID | M02382 |
---|
MarkerDB ID | Not Available |
---|
Good Scents ID | Not Available |
---|
References |
---|
Synthesis Reference | Not Available |
---|
Material Safety Data Sheet (MSDS) | Download (PDF) |
---|
General References | - Zhong J, Lee WH: Lithium: a novel treatment for Alzheimer's disease? Expert Opin Drug Saf. 2007 Jul;6(4):375-83. [PubMed:17688381 ]
- Aghdam SY, Barger SW: Glycogen synthase kinase-3 in neurodegeneration and neuroprotection: lessons from lithium. Curr Alzheimer Res. 2007 Feb;4(1):21-31. [PubMed:17316163 ]
- Kofman O, Belmaker RH: Ziskind-Somerfeld Research Award 1993. Biochemical, behavioral, and clinical studies of the role of inositol in lithium treatment and depression. Biol Psychiatry. 1993 Dec 15;34(12):839-52. [PubMed:8110911 ]
- Waring WS: Management of lithium toxicity. Toxicol Rev. 2006;25(4):221-30. [PubMed:17288494 ]
- Quiroz JA, Machado-Vieira R, Zarate CA Jr, Manji HK: Novel insights into lithium's mechanism of action: neurotrophic and neuroprotective effects. Neuropsychobiology. 2010;62(1):50-60. doi: 10.1159/000314310. Epub 2010 May 7. [PubMed:20453535 ]
|
---|